Lana Pine

Patients with fibromyalgia reported poorer subjective sleep quality compared with controls, although accelerometry parameters showed no significant differences between groups.

Findings demonstrated Danggui Niantong Decoction combined with conventional Western medicine was more effective in treating gout than Western medicine alone.

Although patients in both the intervention and control cohorts gained weight, patients treated with glucocorticoids gained an average of 1.1 kg more than controls.

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

The patient-specific definition of gout remission included minimal symptoms, the absence of dietary restrictions, and management strategies to maintain remission.

Fibromyalgia symptoms were reduced at both 4 and 12 weeks in patients receiving tocilizumab treatment.

The analysis suggested a causal relationship between increased tea intake and overall reduced risk of gout in all 3 gout datasets.

A significantly higher number of total outpatient clinic visits was observed in patients with fibromyalgia compared to controls.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

A cross-sectional analysis showed the reliability and repeatability of the Polish version of the Fibromyalgia Impact Questionnaire were "very good."

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

Albert Roy, president of the Lupus Research Alliance, elaborates on recent initiatives designed to address the underrepresentation of minorities in lupus research.

Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.

Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.

The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).

Common themes among patients and parents included a need to accurately assess pain and offer non-pharmacological options for pain management.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases when compared with controls.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.

The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.

Pediatric rheumatologists were most likely to postpone the decision to withdraw biologic therapy when the patient and/or parents expressed a preference for continuation.

The campaign was inspired by the findings of a global survey conducted with healthcare providers about organ damage in lupus patients.

At the 12-month mark, response rate in patients with uncontrolled gout was significantly higher in those treated with pegloticase and concomitant methotrexate when compared with placebo.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.